CONTACT US
Home > Inhibitors/Agonists> > Teneligliptin
Teneligliptin

Teneligliptin

  • CAT Number: I009753
  • CAS Number: 760937-92-6
  • Molecular Formula: C₂₂H₃₀N6₆OS
  • Molecular Weight: 426.58
  • Purity: ≥95%
Inquiry Now

Teneligliptin (CAT: I009753) is a pharmaceutical drug used for the treatment of type 2 diabetes mellitus. It falls into the class of anti-diabetic drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors or gliptins. Teneligliptin works by inhibiting the enzyme DPP-4, which is responsible for the breakdown of incretin hormones. By inhibiting DPP-4, teneligliptin increases the levels of active incretin hormones, such as glucagon-like peptide-1 (GLP-1), leading to improved glucose control. This medication helps to lower blood sugar levels by promoting insulin release and suppressing glucagon secretion. Teneligliptin is typically used as an adjunct to diet and exercise in the management of type 2 diabetes.

Catalog Number I009753
CAS Number 760937-92-6
Molecular Formula

C₂₂H₃₀N6₆OS

Purity 95%
Target DPP-4 inhibitor
Solubility Soluble in DMSO, not in water
Storage 0 - 4 °C for short term, or -20 °C for long term
Related CAS 906093-29-6 (HCl)
Overview of Clinical Research

<span style=”color:#000000;”><span style=”font-size:12px;”><span style=”font-family:arial,helvetica,sans-serif;”>Teneligliptin is a CD26 antigen inhibitor.&nbsp;Handok Pharmaceuticals initiated a phase I drug interaction trial for Type 2 diabetes mellitus (In volunteers) in South Korea (PO) in July 2020 (NCT04431141)</span></span></span>

IUPAC Name [(2S,4S)-4-[4-(5-methyl-2-phenylpyrazol-3-yl)piperazin-1-yl]pyrrolidin-2-yl]-(1,3-thiazolidin-3-yl)methanone
InChI InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
InChIKey WGRQANOPCQRCME-PMACEKPBSA-N
SMILES CC1=NN(C(=C1)N2CCN(CC2)C3CC(NC3)C(=O)N4CCSC4)C5=CC=CC=C5
Reference

<br />
1:Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice. Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M.Vascul Pharmacol. 2017 Mar 27. pii: S1537-1891(16)30318-4. doi: 10.1016/j.vph.2017.03.003. [Epub ahead of print] PMID: 28347868<br />
2:Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy. Abubaker M, Mishra P, Swami OC.J Clin Diagn Res. 2017 Jan;11(1):OE05-OE09. doi: 10.7860/JCDR/2017/25060.9228. Epub 2017 Jan 1. Review. PMID: 28273997 Free PMC Article<br />
3:A long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, as a preventive drug for the development of hepatic steatosis in high-fructose diet-fed ob/ob mice. Nakamura K, Fukunishi S, Yokohama K, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K.Int J Mol Med. 2017 Apr;39(4):969-983. doi: 10.3892/ijmm.2017.2899. Epub 2017 Feb 20. PMID: 28260070<br />
4:Efficacy and safety of teneligliptin. Singh AK.Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):11-17. doi: 10.4103/2230-8210.193163. No abstract available. PMID: 28217491 Free PMC Article<br />
5:Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M.Diabetes Obes Metab. 2017 Feb 8. doi: 10.1111/dom.12898. [Epub ahead of print] PMID: 28177187<br />
6:Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study). Ghosh S, Trivedi S, Sanyal D, Modi KD, Kharb S.Diabetes Metab Syndr Obes. 2016 Nov 8;9:347-353. eCollection 2016. PMID: 27877058 Free PMC Article<br />
7:Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring. Yajima T, Yajima K, Hayashi M, Takahashi H, Yasuda K.Diabetes Res Clin Pract. 2016 Dec;122:78-83. doi: 10.1016/j.diabres.2016.10.016. Epub 2016 Oct 21. PMID: 27810689<br />
8:Teneligliptin Decreases Uric Acid Levels by Reducing Xanthine Dehydrogenase Expression in White Adipose Tissue of Male Wistar Rats. Moriya C, Satoh H.J Diabetes Res. 2016;2016:3201534. doi: 10.1155/2016/3201534. Epub 2016 Aug 29. PMID: 27652270 Free PMC Article<br />
9:Teneligliptin in management of type 2 diabetes mellitus. Sharma SK, Panneerselvam A, Singh KP, Parmar G, Gadge P, Swami OC.Diabetes Metab Syndr Obes. 2016 Aug 16;9:251-60. doi: 10.2147/DMSO.S106133. eCollection 2016. Review. PMID: 27574456 Free PMC Article<br />
10:The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Pujadas G, De Nigris V, Prattichizzo F, La Sala L, Testa R, Ceriello A.Endocrine. 2017 Jun;56(3):509-520. doi: 10.1007/s12020-016-1052-0. Epub 2016 Aug 16. PMID: 27530507

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!